[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fwsgcO5kZzDtsMV_AGhtwmLCTqQqNsjCY90hOYck02ng":8,"$feMqwghEPjKBuOOeP-MZAqW93T-HToV5ruA4D8gLnB08":55,"$fUGem4naOjq4QY2rhf_LGMhIFSY6QhR36i_H8SOw4fds":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":29,"seoKeywords":30,"seoDescription":31,"shelvesTime":32,"version":20,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},84135,1006984,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//evHXpRDVehplFaP9ZVezqKRlXGKSAY2a.png","马岩","吉林大学第二医院","肿瘤科","主治医师",2,0," 理解弥漫性大B细胞淋巴瘤与R-CHOP化疗的科学用药观指南","","https://ystcdn.venuertc.com/venue/AI/5e473027-cb8d-4950-bcbc-38f5680a3258.jpg","\u003Cdiv class=\"r-chop-material\">\n  \u003Ch1 id=\"material_title\" class=\"r-chop-title\">\n     理解弥漫性大B细胞淋巴瘤与R-CHOP化疗的科学用药观指南\n  \u003C/h1>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#f7f7fc,#edf4fd 70%,#f7f7fc);\">\n    \u003Ch2 class=\"r-chop-section-title\">01 \u003Cspan>R-CHOP治疗组合：药品全览\u003C/span> 🚩\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      R-CHOP是一种常用的联合化疗方案，包含五种药物：利妥昔单抗（Rituximab）、环磷酰胺（Cyclophosphamide）、多柔比星（Doxorubicin，俗称阿霉素）、长春新碱（Vincristine）和泼尼松（Prednisone）。\u003Cbr/>\n      这些药品协同作用，用于特定类型的治疗。每种药物有独立的作用机制、剂型、投用方式以及使用注意事项。接下来，我们将分解这些细节，让大家能轻松掌握关键用药知识。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#f7fafd 50%,#eef5fb);\">\n    \u003Ch2 class=\"r-chop-section-title\">02 \u003Cspan>药品作用机制精讲\u003C/span> 🔬\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-drug-list\">\n        \u003Cli>\n          \u003Cstrong>1. 利妥昔单抗（Rituximab）：\u003C/strong>\n          单克隆抗体，选择性结合CD20抗原，破坏异常B细胞。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>2. 环磷酰胺（Cyclophosphamide）：\u003C/strong>\n          烷化剂，可以抑制DNA复制，干扰细胞增殖。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>3. 多柔比星（Doxorubicin）：\u003C/strong>\n          蒽环类抗生素，通过嵌入DNA链，阻止癌细胞分裂，同时导致细胞凋亡。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>4. 长春新碱（Vincristine）：\u003C/strong>\n          干扰微管装配，阻止细胞有丝分裂完成。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>5. 泼尼松（Prednisone）：\u003C/strong>\n          糖皮质激素，减少炎症反应，诱导异常细胞死亡。\n        \u003C/li>\n      \u003C/ul>\n      这些药品结构和机制各异，组合后相互补充，增强疗效。这是联合化疗的基础，也是安全用药管理的重点。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#eef4fd,#fcfaf9 60%);\">\n    \u003Ch2 class=\"r-chop-section-title\">03 \u003Cspan>剂型与给药方式：如何一步到位\u003C/span> 📦\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-drug-form\">\n        \u003Cli>\n          \u003Cstrong>利妥昔单抗：\u003C/strong>静脉输注，现有浓缩液剂型。\u003Cbr/>\n          \u003Cspan class=\"r-chop-tip\">正确做法：\u003C/span>需按方案规定缓慢滴注，首次输注应特别监测。部分患者可能有输注反应，故要求医疗人员全程监控。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺、多柔比星、长春新碱：\u003C/strong>均为注射液型，静脉输注。\u003Cbr/>\n          \u003Cspan class=\"r-chop-tip\">正确做法：\u003C/span>注射剂量、输注速度及间隔需严格遵从医嘱。绝不能自行调整给药方案。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>泼尼松：\u003C/strong>口服片剂。\u003Cbr/>\n          \u003Cspan class=\"r-chop-tip\">正确做法：\u003C/span>通常于早餐后服用一日全部剂量。应用期间如有不适务必及时反馈。\n        \u003C/li>\n      \u003C/ul>\n      每个药品剂型不同，给药路径决定了药品在体内的分布和发挥速度。\u003Cbr/>\n      \u003Cspan class=\"r-chop-tip\">需要注意：\u003C/span>所有静脉制剂注射需在医院进行，家庭患者严禁擅自注射。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#f7faf7 80%,#f3f0fa);\">\n    \u003Ch2 class=\"r-chop-section-title\">04 \u003Cspan>口服与注射：正确的服药、输注节奏\u003C/span> ⏱️\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-dosage\">\n        \u003Cli>\n          \u003Cstrong>注射药物：\u003C/strong>利妥昔单抗、环磷酰胺、多柔比星、长春新碱均由专业医生、护士操作，周期性给药（常为21天为1周期）。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>口服药物：\u003C/strong>泼尼松按天服用，一般连续5天，随后停药（医嘱为准）。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"r-chop-tip\">正确做法：\u003C/span>泼尼松建议餐后服用，并用足量水整片吞服，不可自行增减剂量或中断。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"r-chop-tip\">需要注意：\u003C/span>静脉药品必须在有经验的医疗团队全程监测下完成，切勿漏剂或提前终止；任何脱档需及时报告。\n        \u003C/li>\n      \u003C/ul>\n      每类药物的服用方式都经过严格论证，按要求执行可减少风险。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#f4f6fa 55%,#f9f7fd);\">\n    \u003Ch2 class=\"r-chop-section-title\">05 \u003Cspan>剂量管理和特殊人群用药须知\u003C/span> 🧑‍⚕️\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-population\">\n        \u003Cli>\n          \u003Cstrong>老年患者：\u003C/strong>\n          需要根据肝肾功能和耐受性调整剂量。部分药物如多柔比星、环磷酰胺对心脏、肾脏和骨髓有抑制风险。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>肝肾功能异常者：\u003C/strong>\n          多柔比星、长春新碱等需要依据生化指标评估后调整投药量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>孕妇、哺乳期女性：\u003C/strong>\n          R-CHOP药品均不推荐使用，有致畸胎和泌乳吸收的风险。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"r-chop-tip\">特别提醒：\u003C/span>所有治疗剂量由医生根据患者体表面积、血象和临床监测综合决定，切勿自行搜集资料修改剂量。\n        \u003C/li>\n      \u003C/ul>\n      临床上，一位63岁女性接受R-CHOP化疗方案，通过严格剂量监控顺利完成周期性治疗，有利于避免副作用。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#f9fbf7,#f5f7fb 88%);\">\n    \u003Ch2 class=\"r-chop-section-title\">06 \u003Cspan>药物相互作用：慎防药效打折\u003C/span> 🧩\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-interaction\">\n        \u003Cli>\n          \u003Cstrong>利妥昔单抗：\u003C/strong>可因配伍不当增加输注反应风险。避免与其他单克隆抗体、免疫调节剂同时使用，除非有明确医嘱。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺、多柔比星：\u003C/strong>需警惕与心脏毒性药品（如部分心脏病药）、肝酶抑制剂联合使用，可能增强副作用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>长春新碱：\u003C/strong>和抗真菌药、某些抗生素合用时，代谢干扰明显，易加重神经毒性。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>泼尼松：\u003C/strong>长期合用抗凝药，可影响凝血功能，并可能干扰血糖控制。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"r-chop-tip\">正确做法：\u003C/span>治疗期间如需使用其他药物，务必提前咨询医生或药师，确保信息互通，防止相互作用隐患。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"r-chop-tip\">任何药物配伍都不可自作主张调整。\u003C/span>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#f8f8fa,#e8f4fb 60%);\">\n    \u003Ch2 class=\"r-chop-section-title\">07 \u003Cspan>常见不良反应及应对方法\u003C/span> 🌡️\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-adverse\">\n        \u003Cli>\n          \u003Cstrong>利妥昔单抗：\u003C/strong>起初可能引起输注反应，如寒颤、皮疹等，多在输注初次出现，通常处理得当可缓解。个别人需要吸氧、抗过敏药。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺、多柔比星、长春新碱：\u003C/strong>主要影响血细胞、消化道、毛发，严重者可能出现骨髓抑制、外周神经毒性，需依照血象、神经系统监测及时调整治疗。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>泼尼松：\u003C/strong>相关副作用包括情绪波动、胃部不适、血糖波动等。\u003Cbr/>正确做法：经常随访并向医生反馈变化，防止副作用加重。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"r-chop-tip\">特别提醒：\u003C/span>\n          如出现过敏、严重消化道出血、心脏异常等罕见反应时，应立即停药并至医院急诊处理。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"r-chop-tip\">不良反应不是停止治疗的唯一标准，切勿恐慌或擅自停药，应依靠医生评估风险。\u003C/span>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#f7f8fa 70%,#faeafa 95%);\">\n    \u003Ch2 class=\"r-chop-section-title\">08 \u003Cspan>用药注意事项与日常管理\u003C/span> 📝\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-care\">\n        \u003Cli>\n          \u003Cstrong>监测血常规：\u003C/strong>规律随访，监控白细胞、血小板及肝肾功能，有异常及时调整药品或剂量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>防感染：\u003C/strong>保持治疗期间局部及全身卫生，远离流感人员，预防并发感染。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>营养补充：\u003C/strong>保证蛋白质、维生素、热量的摄入，避免身体虚弱影响用药效果。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>心理疏导：\u003C/strong>配合积极心态，循序渐进应对治疗副作用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"r-chop-tip\">正确做法：\u003C/span>定期带上所有近期用药说明，让医生全面把握调整空间。\n        \u003C/li>\n      \u003C/ul>\n      用药管理不仅包括按时按量吃药，还涵盖日常的自我监测和生活习惯优化，整体协同，才能确保最大治疗效益。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#fbfaf8 40%,#f5f3fc 85%);\">\n    \u003Ch2 class=\"r-chop-section-title\">09 \u003Cspan>储存和处置：守护药品活性\u003C/span> 🧊\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-storage\">\n        \u003Cli>\n          \u003Cstrong>利妥昔单抗、多柔比星、环磷酰胺、长春新碱注射剂：\u003C/strong>应由专业医院药房储存，大多要求2-8℃冷藏，切勿冷冻或放置高温、高湿环境。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>泼尼松：\u003C/strong>室温干燥储存，避光保存，不可放在潮湿浴室或阳光暴晒处。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>处置规定：\u003C/strong>过期剩余药品应送返医院，由专业团队统一销毁，勿自行处理。\n        \u003C/li>\n      \u003C/ul>\n      药品活性受环境影响显著，管理好存放条件是基础。切记，药品弃置要安全、规范，避免误食和环境风险。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\"  style=\"background:linear-gradient(90deg,#f3fafd,#f7fbfa 60%,#fbf3fa 94%);\">\n    \u003Ch2 class=\"r-chop-section-title\">10 \u003Cspan>漏服与过量：补救措施一览\u003C/span> 🚨\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-miss\">\n        \u003Cli>\n          \u003Cstrong>静脉药物：\u003C/strong>如输注遗漏，一定要第一时间联络医院，请专业人员安排补充或调整方案，不可自行决定。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>口服泼尼松：\u003C/strong>如果忘记服用，当天补服即可；次日再次想起来时，不应双倍剂量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>过量服用：\u003C/strong>如发生过量（尤其是泼尼松或长春新碱），立即停止并就医，告知医生详细用量与时间，配合急救措施。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"r-chop-tip\">补救措施以安全为主，不冒险自行增药、停药。\u003C/span>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#f2fafd 60%,#f9f7fa 90%);\">\n    \u003Ch2 class=\"r-chop-section-title\">11 \u003Cspan>权威数据与典型用药案例\u003C/span> 📊\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      \u003Cul class=\"r-chop-data\">\n        \u003Cli>\n          \u003Cspan>临床研究显示，R-CHOP方案中的不良反应发生率为35-60%，但绝大多数患者在医生指导下能顺利完成既定疗程。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan>有位63岁女性患者在标准R-CHOP化疗期间，因及时血象监测和调整药物使用，未出现严重不适，成功完成4周期给药。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan>药品说明书提示，泼尼松长期使用需特别监控血糖、血压、胃肠功能，遵循逐渐减量停药原则。\u003C/span>\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-section\" style=\"background:linear-gradient(90deg,#f9f7fa 70%,#f8fbfa 95%);\">\n    \u003Ch2 class=\"r-chop-section-title\">12 \u003Cspan>重点总结与合理用药宣言\u003C/span> 🎯\u003C/h2>\n    \u003Cdiv class=\"r-chop-section-body\">\n      细致做好R-CHOP组合用药需要以下三个要点：\u003Cbr/>\n      \u003Col class=\"r-chop-summary\">\n        \u003Cli>严格按照既定方案用药，勿增减剂量\u003C/li>\n        \u003Cli>密切关注不良反应、药物相互作用及特殊人群的剂量调整\u003C/li>\n        \u003Cli>全程保持与医疗团队信息沟通\u003C/li>\n      \u003C/ol>\n      按要求做，可以大降低化疗风险，提高治疗效果。如果对用药有任何疑问，建议及时与医生或药师沟通，不要自行决策。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"r-chop-ref\" style=\"background:linear-gradient(90deg,#eef4fd 80%,#fcf7fa 95%); margin:24px 0 0 0; padding:20px 24px;\">\n    \u003Cstrong>参考文献：\u003C/strong>\n    \u003Col>\n      \u003Cli>Coiffier, B., Lepage, E., Briere, J., et al. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. \u003Ci>New England Journal of Medicine\u003C/i>, 346(4), 235–242. https://doi.org/10.1056/NEJMoa011795\u003C/li>\n      \u003Cli>Sehn, L. H., & Gascoyne, R. D. (2015). Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. \u003Ci>Blood\u003C/i>, 125(1), 22–32. https://doi.org/10.1182/blood-2014-05-538934\u003C/li>\n      \u003Cli>National Comprehensive Cancer Network (NCCN) Guidelines. (2023). B-cell Lymphomas. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf\u003C/li>\n      \u003Cli>Cartron, G., & Watier, H. (2017). Safety of rituximab in B-cell hematologic malignancies. \u003Ci>Expert Opinion on Drug Safety\u003C/i>, 16(7), 875-886. https://doi.org/10.1080/14740338.2017.1331345\u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.r-chop-material {\n  font-family: \"Helvetica Neue\", Helvetica, Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif;\n  color: #262F3D;\n  background: #fbfc;\n  padding: 32px 18px 34px 18px;\n  border-radius: 20px;\n  max-width: 840px;\n  margin: 0 auto;\n  box-sizing: border-box;\n  word-break: break-all;\n  box-shadow: 0 8px 34px rgba(82,100,136,0.07);\n}\n.r-chop-title {\n  text-align: center;\n  font-size: 32px;\n  font-weight: 600;\n  letter-spacing: 2px;\n  color: #304075;\n  margin: 0 0 32px 0;\n  line-height: 1.25;\n  padding: 12px 0;\n  border-radius: 12px;\n}\n.r-chop-section {\n  border-radius: 16px;\n  margin: 22px 0 0 0;\n  box-shadow: 0 2px 12px rgba(110,128,163,0.07);\n  padding: 0 0 0 0;\n}\n.r-chop-section-title {\n  font-size: 22px;\n  font-weight: 500;\n  padding: 15px 19px 9px 22px;\n  letter-spacing: 1px;\n  border-bottom: 1.5px solid #eae8f0;\n  border-top-left-radius: 16px;\n  border-top-right-radius: 16px;\n  margin: 0;\n  color: #4b5078;\n  background: rgba(251,251,255,0.12);\n}\n.r-chop-section-title span {\n  font-weight: 400;\n  margin-left: 8px;\n  color: #6a6f9b;\n}\n.r-chop-section-body {\n  font-size: 17px;\n  line-height: 1.95;\n  padding: 16px 23px 18px 32px;\n  color: #262F3D;\n  min-height: 16px;\n}\n.r-chop-section-body ul,\n.r-chop-section-body ol {\n  margin-left: 0;\n  padding-left: 13px;\n}\n.r-chop-section-body li {\n  margin: 8px 0 0 0;\n  padding: 0 0 0 2px;\n}\n.r-chop-drug-list li,\n.r-chop-drug-form li,\n.r-chop-dosage li,\n.r-chop-population li,\n.r-chop-interaction li,\n.r-chop-adverse li,\n.r-chop-care li,\n.r-chop-storage li,\n.r-chop-miss li,\n.r-chop-data li {\n  margin-bottom: 5px;\n  font-size: 17px;\n  color: #353769;\n}\n.r-chop-section-body .r-chop-tip {\n  font-size: 16px;\n  color: #0e8d71;\n  background: #f3fbf0;\n  margin-left: 8px;\n  border-radius: 7px;\n  padding: 2px 7px;\n  display: inline;\n  font-weight: 500;\n}\n.r-chop-section-body strong {\n  color: #3d2f7e;\n}\n.r-chop-section-body span.r-chop-warn {\n  color: #f06439;\n  font-weight: 500;\n  letter-spacing: 1px;\n  margin-left: 6px;\n}\n.r-chop-summary {\n  margin: 0 0 0 18px;\n  padding: 0;\n  line-height: 2;\n}\n.r-chop-ref {\n  border-radius: 12px;\n  color: #3f4070;\n  font-size: 16px;\n  margin-bottom: 0;\n}\n.r-chop-ref ol {\n  margin: 4px 0 0 14px;\n  padding: 0;\n  line-height: 2;\n  color: #48487a;\n}\n@media screen and (max-width: 540px) {\n  .r-chop-material {\n    padding: 8px 2px 10px 2px;\n    border-radius: 9px;\n    font-size: 97%;\n  }\n  .r-chop-title {\n    font-size: 22px;\n    padding: 9px 0 3px 0;\n    border-radius: 8px;\n  }\n  .r-chop-section-title {\n    font-size: 16px;\n    padding: 10px 10px 5px 13px;\n  }\n  .r-chop-section {\n    border-radius: 9px;\n    box-shadow: 0 1px 5px rgba(110,128,163,0.05);\n  }\n  .r-chop-section-body {\n    font-size: 15px;\n    padding: 12px 7px 15px 9px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"r-chop-material\">\n  \u003Ch1 id=\"material_title\" class=\"r-chop-title\">\n    💊 理解弥漫性大B细胞淋巴瘤与R-",1706,"2026-07-17 14:05:36","💊 理解弥漫性大B细胞淋巴瘤与R-CHOP化疗的科学用药观指南","弥漫性大B细胞淋巴瘤,R-CHOP,化疗方案,用药注意事项,治疗效果,用药机制,癌症药物,患者教育","深入解析R-CHOP化疗方案，帮助患者精准理解用药机制与注意事项。掌握用药技巧，提高化疗效果，保障健康！","2026-07-23 11:00:00",[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":20,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]